NOVYRA PHARMACHEM last traded at ₹8.71 (2026-10-13). Over the past month the stock moved -14.1%, three months the stock moved -37.5%, year the stock moved +34.6%. Its closing range over 52 weeks is ₹6.79 – ₹16.55, with the latest close 47.4% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1987, Bansisons Tea Industries Ltd produces tea, and leases tea garden[1]
Business Overview:[1] The Company is engaged in the business of Pharmaceuticals, Real Estate & Tea Estate.
In the latest quarter (Jun 2026), NOVYRA PHARMACHEM reported sales of ₹1.73 crore and net profit of ₹-0.02 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 1.73 | -0.02 | -1.16 | -0.02 | -0.03 |
| Mar 2026 | 0.10 | -5.33 | -5,330.00 | -5.34 | -8.44 |
| Dec 2025 | 0.00 | -0.02 | – | -0.03 | -0.05 |
| Sep 2025 | 0.00 | 0.00 | – | 0.01 | 0.02 |
| Jun 2025 | 0.00 | -0.03 | – | -0.01 | -0.02 |
| Mar 2025 | 0.00 | -0.07 | – | -0.05 | -0.08 |
| Dec 2024 | 0.00 | -0.01 | – | -0.01 | -0.02 |
| Sep 2024 | 0.00 | 0.00 | – | 0.00 | 0.00 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | – | – | – | – | – | – | – | – |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | – | – | – | – | – |
| EPS growth | – | – | – | – | – | – | – | – |
| OPM % | – | – | – | – | – | – | -5330.0% | -1.2% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), NOVYRA PHARMACHEM reported sales of ₹0.10 crore and net profit of ₹-5.37 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 0.10 | -5.40 | -5,400.00 | -5.37 | -8.48 |
| Mar 2025 | 0.00 | -0.04 | – | -0.06 | -0.09 |
| Mar 2024 | 0.00 | -0.14 | – | -0.16 | -0.25 |
| Mar 2023 | 0.15 | 0.04 | 26.67 | 0.01 | 0.02 |
| Mar 2022 | 0.15 | -0.02 | -13.33 | 0.00 | 0.00 |
| Mar 2021 | 0.15 | 0.06 | 40.00 | 0.08 | 0.13 |
| Mar 2020 | 0.15 | 0.00 | 0.00 | -0.02 | -0.03 |
| Mar 2019 | 1.72 | -0.10 | -5.81 | -0.13 | -0.21 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -0.6% | -91.3% | +0.0% | +0.0% | +0.0% | -100.0% | – | – |
| Operating profit growth | – | – | – | -133.3% | – | -450.0% | – | – |
| Net profit growth | – | – | – | -100.0% | – | -1700.0% | – | – |
| EPS growth | – | – | – | -100.0% | – | -1350.0% | – | – |
| OPM % | -5.8% | 0.0% | 40.0% | -13.3% | 26.7% | – | – | -5400.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for NOVYRA PHARMACHEM.
Get Free AI Stock Analysis FREE →Bansisons Tea Industries reports standalone net loss of Rs 0.02 crore in the June 2026 quarter - Business Standard
Bansisons Tea Industries reports standalone net loss of Rs 0.02 crore in the June 2026 quarter - Business Standard
Bansisons Tea Industries reports standalone net loss of Rs 0.02 crore in the June 2026 quarter - Business Standard
NOVYRA PHARMACHEM shares were last quoted at ₹8.71 (-4.9% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
NOVYRA PHARMACHEM has a price-to-earnings (P/E) ratio of -1.08 and a price-to-book (P/B) ratio of 9.65. The industry P/E is 55.80.
The 52-week high of NOVYRA PHARMACHEM is ₹16.55 and the 52-week low is ₹5.88.
The market capitalisation of NOVYRA PHARMACHEM is about ₹5.80 crore.
In the latest quarter (Jun 2026), NOVYRA PHARMACHEM reported sales of ₹1.73 crore and net profit of ₹-0.02 crore, compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, NOVYRA PHARMACHEM has a 3-year ROE of -37.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 23.15% of NOVYRA PHARMACHEM.
NOVYRA PHARMACHEM belongs to the Tea/Coffee sector.